Harmine

• Description:

  Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM[1].

• Product Name Alternative:

  Telepathine

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  5-HT Receptor; DYRK

• Type:

  Natural Products

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Harmine.html

• Concentration:

  10mM

• Purity:

  99.97

• Solubility:

  DMSO : ≥ 30 mg/mL

• Smiles:

  CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3

• Molecular Formula:

  C13H12N2O

• Molecular Weight:

  212.25

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Glennon RA, et al. Binding of beta-carbolines and related agents at serotonin (5-HT (2) and 5-HT (1A) ), dopamine (D (2) ) and benzodiazepine receptors. Drug Alcohol Depend. 2000 Aug 1;60 (2) :121-32.|[2]Neumann F, et al. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep. 2018 Feb 12;8 (1) :2859.|[3]Zhang L, et al. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther. 2015;16 (11) :1585-92.|[4]Zhong Z, et al. Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury. Mol Med Rep. 2015 Dec;12 (6) :7985-91.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  Phase 1

• Isoform:

  5-HT2 Receptor; DYRK1; α-1 microglobulin

• Citation 01:

  Biochem Pharmacol. 2025 Oct 7;242 (Pt 4) :117391.|Biomedicines. 2024 Jan 16;12 (1) :197.|bioRxiv. 2023 Dec 1.|BMC Infect Dis. 2024 Jul 31;24 (1) :760.|Cancer Biol Med. 2020 May 15;17 (2) :387-400.|Cell Stem Cell. 2022 Apr 7;29 (4) :545-558.e13.|Eur J Pharmacol. 2024 Dec 30:177223.|Eur J Pharmacol. 2024 Jul 31:980:176828.|Exp Ther Med. 2022 Mar;23 (3) :209.|Int Immunopharmacol. 2023 Jun:119:110208.|Int Immunopharmacol. 2026 Jan 1;168 (Pt 2) :115902.|Int J Oncol. 2022 Apr;60 (4) :45.|J Biol Chem. 2025 Feb 2:108254.|J Biomed Sci. 2022 Jun 2;29 (1) :34.|J Cell Mol Med. 2019 Nov;23 (11) :7427-7437.|J Clin Invest. 2024 Jul 18:e179472.|J Ethnopharmacol. 2025 Jan 30;337 (Pt 3) :118896.|Onco Targets Ther. 2019 Jun 12:12:4585-4593.|Phytomedicine. 2025 May:140:156484.|Phytomedicine. 2025 Sep 24:148:157306.|Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79 (Pt B) :258-267.|Res Sq. 2025 Jul 08.|Research Square Preprint. 2021 Aug.|Sci Adv. 2023 Dec 22;9 (51) :eadi5683.|Sci Rep. 2015 Aug 3;5:12728.|Sci Rep. 2024 Mar 18;14 (1) :6504.|SSRN. 2023 Mar 8.|Front Cell Dev Biol. 2022 Jan 17;9:792257.|J Integr Neurosci. 2025 Jun 23;24 (6) :38100.

• CAS Number:

  442-51-3